Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A randomized low-intervention phase II trial of the AIO working groups breast cancer and quality of life

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504141-31-00

Acronym

DISCUSS

Enrollment

120

Registered

2023-11-10

Start date

2024-01-17

Completion date

Unknown

Last updated

2025-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 negative breast cancer, Metastatic HR positive

Brief summary

Progression-free survival rate 12 months after randomization (PFS@12_stopping), defined as proportion of patients alive and without progression according to radiologic imaging assessment

Interventions

DRUGEXEMESTANE

DRUGFULVESTRANT

DRUGPALBOCICLIB

DRUGLETROZOLE

DRUGABEMACICLIB

DRUGANASTROZOLE

DRUGRIBOCICLIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival rate 12 months after randomization (PFS@12_stopping), defined as proportion of patients alive and without progression according to radiologic imaging assessment	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026